The usefulness of rapid growth hormone (GH) measurement was retrospectively evaluated as an indicator of total tumor removal during surgery and compared with several reported criteria in 252 acromegalic patients who underwent transsphenoidal surgery at Toranomon Hospital between 2006 and 2008. GH levels were measured in blood samples obtained before surgery, at the start of tumor removal, and every 20 minutes thereafter until 20 minutes after total tumor removal as judged by the operator. Intraoperative GH dynamics were compared between 201 patients fulfilling the Cortina consensus criteria (successful group) and 37 patients who did not (unsuccessful group). Among several criteria indicating total tumor removal, only the ratio of serum GH level 20 minutes after the end of tumor removal to GH level at the end of tumor excision was significantly different between the groups; a reduction ratio of 65% was the most appropriate cut-off value based on sensitivity (59.2%) and specificity (59.5%). The ratio of GH level 20 minutes after the end of tumor removal/GH level at the end of tumor excision was the most reliable index to judge tumor removal during surgery, but this index is neither necessary nor sufficient and should be used as one of the indicators to judge complete tumor removal during surgery.
Introduction
Transsphenoidal surgery is the first choice for the treatment of acromegaly. Many preoperative factors, including serum growth hormone (GH) values, tumor size, and tumor invasion into the cavernous sinus can affect surgical results. However, maximum tumor removal is important to optimize the possibility of cure by postoperative adjuvant therapies including chemotherapy and radiation, even in patients in whom total tumor removal seems impossible. Therefore, a method for intraoperative assessment of complete tumor removal would be very useful. Intraoperative rapid GH measurement has been developed and utilized in many institutions for this purpose. [1] [2] [3] [4] [5] [7] [8] [9] However, no consensus has been reached on the criteria for complete tumor removal during surgery. We have used a specially-developed rapid GH assay to assess tumor removal during surgery since 1981. This study retrospectively evaluated the surgical outcomes and the findings of rapid GH measurement to validate the usefulness of this method, and attempted to establish more appropriate criteria to predict complete tumor removal by comparing previously proposed criteria.
Materials and Methods
This study included a total of 252 acromegalic patients aged 18 to 74 years, 120 men (mean age 43.4 years) and 132 women (mean age 50.1 years), who underwent transsphenoidal surgery at Toranomon Hospital in Tokyo between January 2006 and May 2008. Long-acting octreotide (Sandostatin LAR  ; Sandoz GmbH, Schaftenau, Austria) (20 mg) was administered once at 5 weeks before surgery in 47 of the 252 patients to reduce the size of the adenoma. Transsphenoidal surgery was performed using the same method by a single surgeon (S.Y.) under anesthesia as primary surgery in 214 patients with acromegaly or as secondary surgery for the recurrence or persistence of the disease in 24 patients. Anesthesia used the same protocol and the same agents including propofol, vecuronium, and fentanyl in all patients.
Intraoperative GH levels were measured before surgery, at the start of tumor removal, and every 20 minutes thereafter until 20 minutes after presumed complete tumor excision as judged by the surgeon. Measurement of GH values takes approximately 30 minutes after submitting blood samples to the laboratory. GH and insulin-like growth factor-1 (IGF-1) were measured by enzyme immunoassay. The time required for tumor removal was dependent on several factors including tumor size, tumor consistency, and invasion into the cavernous sinus, and was approximately 50 minutes (range 20 to 200 minutes) in this series.
GH has been measured by Immuno Enzymometric assay (ST AIA-PACK HGH; Tosoh Corporation, Tokyo) since May 1, 2005 . The minimum detectable concentration was 0.07 ng/ml. The interassay coefficients of variation were 3.1% at 0.39 ng/ml, 3.4% at 4.68 ng/ml, and 4.8% at 17.68 ng/ml, and the intra-assay coefficients of variation were 2.9% at 0.38 ng/ml, 2.3% at 4.83 ng/ml, and 1.4% at 17.98 ng/ml. The World Health Organization 2nd International Standard 98/574 was used as the GH standard. Serum IGF-1 levels were determined using the commercially available``Daiichi'' IGF-1 IRMSA immunoradiometric assay (Fijifilm RI Pharma Co., Ltd., Tokyo). The kit standards were derived from recombinant human IGF-1, which was originally calibrated using the International Reference Preparation 87/518. The interassay coefficients of variation were 3.9% at 48 ng/ml, 3.0% at 148 ng/ml, and 4.1% at 634 ng/ml, whereas the intra-assay coefficients of variation were 2.4% at 52.2 ng/ml, 3.5% at 161 ng/ml, and 2.2% at 612 ng/ml. The IGF-1 range was chosen to encompass the published physiological range across sexes and various age groups. 6) Postoperative endocrine data obtained 1 year after surgery were assessed based on the Cortina consensus criteria, which have been widely used in this field. 3) The criteria for successful surgical outcome included suppression of GH to º1 mg/l after a 75-g oral glucose tolerance test (OGTT) and normal serum IGF-1 concentration. If both criteria were not fulfilled, the surgical outcome was considered unsuccessful.
All continuous data are expressed as mean ± standard error (SE). All variables not normally distributed were compared using the Mann-Whitney test. The x 2 test was used to assess differences between categorical variables. A two-tailed p value º0.05 was considered statistically significant.
Results
Surgery was assessed as successful in 201 (79.8%) of the 252 patients with acromegaly (successful group), and unsuccessful in 37 (14.7%) (unsuccessful group). The remaining 14 patients (5.6%) were excluded from this study because only one of the two conditions was fulfilled (normalization of IGF-1 was not achieved in 3, and nadir GH levels after 75-g OGTT were greater than 1 mg/l in 11 patients). Of the 47 patients who received preoperative octreotide, 39 (19%) were among the 201 patients with successful surgery, and 8 (22%) were among the 37 patients with unsuccessful surgery (p ＝ 0.97). Primary surgery was performed in 180 patients (90%) in the successful group and in 34 patients (92%) in the unsuccessful group (p ＝ 0.92). Tumor invasion into the cavernous sinus, which was suspected on preoperative magnetic resonance imaging and confirmed by operative findings, was found in 70 (29%) of the 238 patients in this series, and was significantly more common in the unsuccessful group (59%, 22/37) than in the successful group (24%, 48/201) (p ＝ 0.003). Changes in GH levels during surgery in the successful and unsuccessful groups are presented in Fig. 1 . The GH values generally rose rapidly and peaked after the start of tumor removal, and then decreased gradually during tumor removal in successful patients. This pattern was not seen in unsuccessful patients. The reduction ratio, calculated as the GH level at 20 minutes after the end of tumor removal divided by the GH level at the end of tumor resection, of Ã50% was seen more frequently in the successful group, whereas no consistent trend was seen in the unsuccessful group (Fig. 2) . In addition, the mean (±SE) reduction ratio was significantly lower in the successful group (0.64 ± 0.016) than in the unsuccessful group (0.81 ± 0.053, p ＝ 0.0007).
When the cut-off value was set at 50% according to Abe's criteria, 1) the reduction ratio was Ã50% in only 49 (24.4%) of the 201 patients in successful group, whereas the ratio was À50% in 31 (83.8%) of the 37 patients in unsuccessful group (Table 1) . In addition, a ratio Ã50% was found in only 3 (12.5%) of the 24 patients in successful group with a GH level À40 mg/l before tumor removal, and a ratio À50% was found in 10 (83.3%) of the 12 patients in unsuccessful group (Table 1) , showing that the 50% cut-off was a poor indicator of tumor removal during sur- gery. This trend was seen regardless of preoperative octreotide use or the presence of tumor invasion into the cavernous sinus (Table 1 ). This study found that a reduction ratio of 65% was the most appropriate cut-off value based on the sensitivity (59.2%) and specificity (59.5%) in this series (Table 1) . To evaluate the criterion proposed by van den Berg et al., 8) we examined how much time was required for the GH level to decrease by half from the end of tumor removal. This was calculated in each case as follows: rate of decline per minute ＝ (value at the end of removal -value at 20 minutes after the end of removal)/20; and half-life (min) ＝ (GH value at the end of removal)/2 × 1/(rate of decline per minute). The mean GH half-life calculated by this formula was 29.3 ± 1.91 minutes in the successful group and 45.6 ± 17.17 minutes in the unsuccessful group, with no significant difference (p ＝ 0.2513).
Several other factors were also assessed for utility in distinguishing the two groups during surgery using rapid GH measurement. The mean ratio of the GH level at 20 minutes after the end of tumor removal divided by the value at the start of removal was not significantly different between the groups (mean ± SE was 47.6 ± 6.23 in the successful group Rapid GH Measurement During Transsphenoidal Surgery and 29.9 ± 6.0 in the unsuccessful group, p ＝ 0.2081). The ratio of the value at 20 minutes after the end of tumor removal to the highest value during removal was also not significantly different (mean ± SE was 23.9 ± 1.3 in the successful group and 23.5 ± 2.8 in the unsuccessful group, p ＝ 0.9679). Similarly, the slope of the line between the highest value during removal and the value at 20 minutes after the end of removal ([highest value during removal -value at 20 minutes after the end of removal]/time) was also not significantly different between the groups (mean ± SE was 3.1 ± 0.2 in the successful group and 4.2 ± 0.9 in the unsuccessful group, p ＝ 0.3659).
Discussion
This study evaluated the usefulness of intraoperative rapid GH measurements for predicting complete tumor removal during surgery and assessed the most reliable criteria among several previously proposed criteria using a large series of acromegalic patients. The GH dynamics during surgery may be affected by many factors such as preoperative medications, past history of surgery for acromegaly, tumor size, the degree of cavernous sinus invasion, type of anesthetic, and renal function. Indeed, it would be logical to check all these factors that may influence the GH measurement and to consider the differences of these factors in assessing the results in each case. However, it is not only complicated, but also not practical to consider all these factors in the application of the rapid GH measurement during surgery in the clinical setting. In fact, the differences in these factors have not been taken into account in other studies assessing the results of rapid GH measurement during surgery. 1, 8, 9) However, the present study clarified that neither preoperative octreotide treatment nor tumor cavernous sinus invasion influenced the utility of intraoperative rapid GH measurement to assess tumor removal.
Serum GH level Ã4.5 mg/l at 60 minutes after the end of tumor removal was reported as the best predictor of postoperative radical tumor removal, although reduction ratio À50% in the GH level at 20 minutes compared to 0 minutes after the end of tumor resection was considered better in the cases with intraoperative GH concentrations AE40 mg/l prior to tumor resection. 1) We also examined these indicators in our patients. Serum GH level was not a good predictor of tumor removal, but the reduction ratio (GH level at 20 minutes after the end of removal/GH level at the end of tumor resection) was significantly different between the successful and unsuccessful groups, indicating that this reduction ratio may be useful in distinguishing the two groups during surgery. However, the detection rate was low in the successful group (sensitivity 24.4%, specificity 83.8%) using a cut-off value of 50%. These criteria were previously applied only to cases with GH levels more than 40 mg/l before tumor removal, 1) but similarly the detection rate was 12.5% for the successful group and 83.3% for the unsuccessful group in the present series. In contrast, both sensitivity and specificity increased to 59.2% and 59.5%, respectively, using a cut-off value of 65%. Therefore, 65% is a more appropriate cut-off value than 50%.
GH level was previously measured at the end of tumor removal as a starting point, and then GH levels were measured every 5 minutes. 8) The best indicator of tumor removal was found to be the time taken for GH levels to reach half of the level measured at the end of tumor removal, with sensitivity of 77% and specificity of 100% using the cut-off value for the GH half-life of 25 minutes, although only 20 cases were examined. 8) GH half-life was also investigated in the large number of patients in this study, but no significant difference was found between the groups, indicating that GH half-life is not a useful indicator of tumor removal during surgery. Moreover, the high sensitivity (77%) and specificity (100%) were not reproducible in this study with detection rates of 54.2% for the successful group and 56.8% for the unsuccessful group.
In addition, several other factors, including the ratio of the GH level at 20 minutes after the end of tumor removal to the level at the start of removal, the ratio of the value at 20 minutes after the end of removal to the highest value during removal, and the slope of the line between the highest value during removal and at 20 minutes after the end of removal, were evaluated, but no significant differences were found between the groups. These results suggest that none of these factors can completely distinguish between successful and unsuccessful cases during surgery.
Analysis of the present large series of 238 patients with acromegaly who underwent transsphenoidal surgery found that the ratio of the GH value obtained at 20 minutes after the end of tumor removal to the value obtained at the end of removal is the most reliable indicator of whether complete tumor removal was achieved, using a cut-off value of 65% with sensitivity and specificity of approximately 60%. However, the results obtained from these rapid GH measurements during surgery were not necessary or sufficient conditions, so should be used only as one of the tools to assess complete tumor excision during surgery.
